New Hampshire Senate Approves Recreational Marijuana Bill

For the first time ever, the New Hampshire Senate has given approval to legislation that would legalize recreational marijuana.

House Bill 1633 passed the full Senate today through its second reading by a vote of 14 to 9. It will now go to the Senate Finance Committee and then to a third and final reading by the Senate, expected next week, before it can be sent back to the House of Representatives. The House passed the bill last month by a vote of 239 to 136. However, since it was amended in the Senate, the House will need to concur with the changes before the measure can be sent to Governor Chris Sununu.

If the House disagrees with the Senate’s changes, a conference committee consisting of members from both chambers will be established with the hopes of reaching a consensus.
Continue reading

Maryland Governor Signs Psychedelics Bill Into Law

Maryland Governor Wes Moore has signed into law legislation that establishes a psychedelics task force.

Psilocybin (top left), mescaline (top right), DMT (bottom left), and psilocin (bottom right), the four substances that will be covered by the new task force.

Senate Bill 1009 was passed unanimously through the full legislature, with the vote being 137 to 0 in the House of Representatives and 45 to 0 in the Senate.

The new law will establish a “Task Force on Responsible Use of Natural Psychedelic Substances to study and make recommendations related to the use of natural psychedelic substances; and requiring the Task Force to submit a report of its findings and recommendations to the Governor and the General Assembly on or before July 31, 2025.”
Continue reading

The DEA Has Published Rules to Reschedule Marijuana: Here’s What Comes Next

Today, the Drug Enforcement Administration (DEA) officially published its proposed rules that would move marijuana to Schedule III. Here’s a look at the next steps to make the change final.

The 92-page notice published today by the DEA (a branch of the Department of Justice) states that the federal government plans to move marijuana from its current status as a Schedule I drug to a Schedule III drug, based on its currently accepted medical value. The notice’s publication coincided with a social media video announcement by President Biden.

The DEA publishing the proposed rules in the Federal Register indicates that they’ve received approval from the White House Office of Management and Budget. Now that the notice has been published, it initiates a 60-day public comment period, which is legally required for any changes to the Controlled Substances Act.
Continue reading

119th US Lawmaker Joins as Sponsor to SAFE Banking Act

119 members of the United States House of Representatives are now sponsoring the SAFE Banking Act to allow marijuana banking.

(Photo credit: GETTY Images).

Yesterday, Congressmember Chris Deluzio (D-PA) signed on as a cosponsor for the SAFE Banking Act, bringing the total number of sponsors to 119 (109 more than when it was filed last April). The proposed law would allow banks and credit unions to provide financial services to marijuana businesses that are licensed under state law. A Senate version of the measure —the SAFER Banking Act— currently has 36 sponsors and has been passed through the Senate Banking Committee.

The SAFE Banking Act would also remove an IRS rule that prohibits marijuana businesses from taking standard tax deductions even if they’re legal under their state’s laws.
Continue reading

US Justice Department Submits Proposed Regulation to Reschedule Marijuana to Schedule III

The United States Department of Justice (DOJ) has officially published a notice detailing its proposal to reclassify marijuana as a Schedule III substance.

The Justice Department today announced that the Attorney General has submitted to the Federal Register a notice of proposed rulemaking initiating a formal rulemaking process to consider moving marijuana from a schedule I to schedule III drug under the Controlled Substances Act (CSA).

“Marijuana has been classified as a schedule I drug since Congress enacted the CSA in 1970. On Oct. 6, 2022, President Biden asked the Attorney General and the Secretary of Health and Human Services (HHS) to launch a scientific review of how marijuana is scheduled under federal law”, states a press release from the Department of Justice. “After receiving HHS’s recommendations last August, the Attorney General sought the legal advice of the Justice Department’s Office of Legal Counsel (OLC) on questions relevant to this rulemaking. In light of HHS’ medical and scientific determinations, and OLC’s legal advice, the Attorney General exercised his authority under the law to initiate the rulemaking process to transfer marijuana to schedule III.”
Continue reading

Vice President Harris Publishes First Video on Marijuana Rescheduling, Thanks Advocates

Vice President Kamala Harris has released her first video on the marijuana rescheduling news.

“So currently, marijuana is classified on the same level as heroin and more dangerous than fentanyl”, Vice President Harris says in the video, published on the social media platform “We are finally changing that. I want to thank all of the advocates and everyone out there for helping to make this possible.”

Harris says “we are on the road to getting it done.”
Continue reading

President Biden Releases Video Announcing Marijuana Rescheduling, Calling it “Monumental”

President Biden has released a video on the social media platform X officially announcing that marijuana will be moved to Schedule III.

“This is monumental. Today my administration took a major step to reclassify marijuana from a Schedule I to a Schedule III drug”, said President Biden in the video. “It’s an important move towards reversing longstanding inequities.”

Biden says “Today’s announcement builds on the work we’ve already done to pardon a record number of federal offenses for simple possession of marijuana. It adds to the action we’ve taken to lift barriers to housing, employment, small business loans, and so more for tens of thousands of Americans.”
Continue reading

BREAKING: Department of Justice to Officially Publish Marijuana Rescheduling Plans Today

The Department of Justice (DOJ) plans to publish a notice today that details its proposal to reclassify marijuana to Schedule III, according to multiple officials with the Biden Administration.

The notice being posted comes a little over two weeks after the Department of Justice confirmed that marijuana is being moved to Schedule III. Today’s notice from the DOJ indicates that the move has been approved by the White House Office of Management and Budget. Once the notice is posted, a legally required 60-day public comment period will begin soon after.

Under current law, marijuana is classified as a Schedule I drug, rendering it illegal for all purposes. By reclassifying marijuana to Schedule III, it will effectively be legalized nationwide for prescription use. This change will also provide numerous federal protections to state-legal medical marijuana patients and businesses, which are currently unavailable under the existing classification.
Continue reading

US Lawmakers From Over 40 States Now Sponsoring Federal Marijuana Banking Legislation

Federal legislation to allow marijuana banking is now sponsored by lawmakers from 41 different states, demonstrating its widespread and bipartisan support.

In the House of Representatives, the SAFE Banking Act has 118 sponsors, more than any marijuana-related bill in US congressional history. In the Senate, the similar SAFER Banking Act has 36 sponsors. Combined, these measures have sponsors from 41 states, 82% of the entire country.

Both measures would allow accredited banks and credit unions to provide a suite of banking services, including debit card processing and loans, to marijuana businesses that are following their state’s laws. Despite state licensing, these businesses are currently unable to access banking services due to federal restrictions, compelling many to operate solely with cash and heightening their risk of theft.
Continue reading

Study Says CBD is a “Promising Tool for Refractory Epilepsy in Pediatric Patients”

The cannabis-compound cannabidiol (CBD) is a promising option for treating refractory epilepsy in pediatric patients, according to a new study.

The study, titled “Use of Cannabidiol in the Treatment of Drug-Refractory Epilepsy in Children and Young Adults: A Systematic Review”, was conducted by researchers at the Rafael Nuñez University Corporation in Colombia and published in the Journal of Neurosciences in Rural Practice. It was also epublished by the National Library of Medicine.

According to the study “Epilepsy poses a significant challenge in pediatric and adolescent populations, impacting not only seizures but also psychological and cognitive comorbidities, leading to higher mortality rates than the general population”. It notes that “Drug-refractory epilepsy, resistant to conventional treatments, affects a range of 7-20% of pediatric patients. The search for alternative therapies has led to exploring the therapeutic potential of Cannabis sativa L. compounds, particularly cannabidiol (CBD).”
Continue reading